Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Presentation (December 2025)
26 slides from Diasorin's investor presentation, December 2025
Slide 1: Diasorin Company Presentation
DIASORIN COMPANY PRESENTATION
Slide 2: About us
About us World leaders in the lab diagnostics market, we are specialists in the immunodiagnostic and molecular diagnostic segments and active in the Licensed Technologies business We have been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50
Slide 3: Our business
Our business In Vitro Licensed Diagnostics Technologies 3 Diasorin Company Presentation
Slide 4: Our business: In Vitro Diagnostics and Licensed Technologies
Our business In Vitro Diagnostics Licensed Technologies We market and develop diagnostic tests We enable scientists get quick and reliable and solutions in the immunodiagnostic responses to complex biological issues with and molecular diagnostic sectors. innovative and unique solutions supporting di
Slide 5: From needs to our solutions
From needs to our solutions Healthcare sector clients need to The doctor prescribes DEVELOP A NEW PRODUCT DIAGNOSTIC TESTS (drug, test, vaccine, etc.) The patient has * SAMPLES taken in a Luminex LTG provides the healthcare facility or PLATFORM FOR RESEARCH A patient gets tested into a laboratory an
Slide 6: Our story
Our story Diasorin receives FDA 510(k) Diasorin acquires the US company Diasorin sells all the assets clearance for LIAISON NES Diasorin continues to grow organically Luminex Corporation for $1.8bn, thus Foundation of SORIN, a Diasorin stock is included in related to the Flow Cytometry and its ABCR
Slide 7: Diasorin worldwide
Diasorin worldwide NORTH AMERICA 50% of Group Revenues* EUROPE 35% of Group Revenues* REST OF WORLD 15% of Group Revenues* 3271 Employees *data as of December 31, 2024 7 Diasorin Company Presentation
Slide 8: Financials and Guidance FY 2025
Financials Guidance FY 2025 @CER: 1361 • Ex-Covid Revenues: 1238 ~ +5% (Covid 1185 Revenues ~ 10€/mln) 1148 • Total Revenues: ~+4% 881 • Adj. EBITDA Margin: ~ 33% 706 669 637 569 543 499 514 440 434 435 444 404 385 394 375 304 255 277 245 238 202 217 167 190 170 185 163 160 124 86 60 2007 2008 2009
Slide 9: Our business by tech
Our business* by tech 16% Licensed Technologies 18% Molecular Diagnostics 66% Immunodiagnostics *ex-Covid business 9 Diasorin Company Presentation Data as of December 31, 2024
Slide 10: M&A and Partnerships
M&A and Partnerships LIAISON NES Bacterial vs. Viral platform infection testing B·R·A·H·M·S GI Stool testing Connectivity for Hepatitis QuantiFERON lab automation & Retrovirus Technology MR-proADM test PARTNERSHIPS 2000 - 2009 2010 - 2014 2015 - 2019 2020 - Today Byk Sangtec CLIA Parvovirus test ELI
Slide 11: Our Immunodiagnostic Systems
Our Immunodiagnostic Systems LIAISON® XS LIAISON® XL LIAISON® XL LAS LIAISON® XL 2.0* * To be launched Small-to-medium labs Medium-to-large labs DISEASE AREAS • Infectious diseases • Autoimmunity • Bone & mineral • Endocrinology • Hypertension • Oncology • Gastrointestinal diagnostics • Emergency/Se
Slide 12: The LIAISON XL assay menu
INFECTIOUS DISEASES Toxo IgG II The LIAISON® XL assay menu Toxo IgM Toxo IgG Avidity Rubella IgG II Rubella IgM CMV IgG II CMV IgM II CMV IgG Avidity II HSV-1/2 IgG HSV-1 IgG HSV-2 IgG METABOLIC DISORDERS TUMOR GASTROINTESTINAL HEPATITIS AND ENDOCRINOLOGY ENDOCRINOLOGY INFECTIOUS DISEASES HSV-1/2 Ig
Slide 13: The LIAISON XS assay menu
The LIAISON® XS assay menu INFECTIOUS DISEASES Toxo IgG II Toxo IgM Toxo IgG Avidity Rubella IgG II Rubella IgM CMV IgG II CMV IgM II CMV IgG Avidity II HSV-1/2 IgG METABOLIC DISORDERS TUMOR GASTROINTESTINAL HEPATITIS AND ENDOCRINOLOGY INFECTIOUS DISEASES HSV-1 IgG 25-OH Vitamin D TOTAL MARKERS DISE
Slide 14: Our Molecular Diagnostic Systems
Our Molecular Diagnostic Systems * To be launched LIAISON® NES LIAISON® MDX LIAISON® MDX Plus* Luminex® 100/200 MAGPIX® Verigene® LIAISON® PLEX Non-automated Non-automated Automated Automated Single-low Plex Platforms Multiplexing Platforms Detects the presence of up to 5 pathogen agents starting fr
Slide 15: LIAISON NES
LIAISON® NES The LIAISON® NES is a new molecular platform to address the growing diagnostic decentralization trend that is driving the need for fast and accurate testing in laboratory and near-patient settings. The LIAISON® NES will offer high quality, cost effective low-plex testing, generating res
Slide 16: LIAISON MDX and LIAISON MDX Plus
LIAISON® MDX and LIAISON® MDX Plus LIAISON® MDX LIAISON® MDx The LIAISON® MDX is an innovative and powerful thermocycler with two consumable disc options: the 8- well Direct Amplification Disc for sample-to-answer testing and the 96-well Universal Disc for higher volume testing. Supported by an expa
Slide 17: The LIAISON MDX and ASRs/RUO menu
The LIAISON® MDX and ASRs/RUO menu single low plex single low plex LIAISON® MDX LIAISON® MDX LIAISON® MDX LIAISON® MDX (DAD kits) (UD kits) ASR(s)/RUO (DAD kits) (UD kits) ASR(s)/RUO Respiratory Hospital Bordetella X X X Acquired Group A Strep X X Infections Flu A/B & RSV X X C. difficile X X X COVI
Slide 18: The LIAISON MDX and ASRs/RUO menu
The LIAISON® MDX and ASRs/RUO menu single low plex single low plex LIAISON® MDX LIAISON® MDX LIAISON® MDX LIAISON® MDX (DAD kits) (UD kits) ASR(s)/RUO (DAD kits) (UD kits) ASR(s)/RUO Women's Vector/tick Health Borne HSV 1&2 X X Dengue X X VZV (SWAB) X X Anaplasma X HSV 1/2 & VZV X X Babesia X GBS X
Slide 19: MAGPIX
MAGPIX® MAGPIX® This compact multiplexing unit performs up to 50 different tests in a single reaction volume and reads a 96-well plate in just 60 minutes. MAGPIX ® features self-cleaning routines and magnetic bead compatibility (with MagPlex® beads), making the instrument easy to learn and easy-to-u
Slide 20: Luminex 200
LUMINEX® 200 The Luminex® 200™ System is a flexible analyzer based on the principles of flow cytometry that enables Luminex® 200 you to multiplex (simultaneously measure) up to 100 analytes in a single microplate well, using very small samples. The system delivers fast and cost-effective bioassay re
Slide 21: Verigene
VERIGENE® The VERIGENE® System instrumentation consists of a VERIGENE ® Reader and one or multiple VERIGENE® Processor SPs. The VERIGENE® Reader manages sample information, reads results from processed cartridges, and allows for result printing, internal data storage, and LIS connectivity without Ve
Slide 22: LIAISON PLEX
LIAISON® PLEX The LIAISON® PLEX System is a sample-to-answer molecular diagnostic platform capable of performing multiplex testing on a single sample. The system is fully-integrated and performs extraction, amplification, hybridization, and detection-all in one cartridge. Its proprietary Flex® Softw
Slide 23: MAGPIX, Luminex 200, Verigene and LIAISON PLEX menu
MAGPIX®, LUMINEX® 200, VERIGENE® and LIAISON® PLEX menu multiplexing MAGPIX® LUMINEX® 200 VERIGENE® LIAISON® PLEX X Submitted to the Gastrointestinal Panel X X FDA X Respiratory Panel X X X Bloodstream Infection Panels X X* Genetics Cystic Fibrosis Panels X CYP 2C19 X X *The LIAISON PLEX® Blood Cult
Slide 24: Our Licensed Technologies Systems
Our Licensed Technologies Systems xMAP INTELLIFLEX® FLEXMAP 3D® Luminex® 200 MAGPIX® Up to 500 analytes Up to 500 analytes Up to 100 analytes Up to 50 analytes per sample per sample per sample per sample Licensed Technologies Group MAIN APPLICATIONS • Allergy Testing Factors • Metabolic Markers • Ne
Slide 25: Luminex xMAP INTELLIFLEX platform
Licensed Technologies: Luminex xMAP INTELLIFLEX® platform Reliable, sensitive results Customization and flexibility Maximum data/answers 500 analytes per well; up to 2 parameters per analyte 25 Diasorin Company Presentation
Slide 26: Diasorin S.p.A. www.diasorin.com
Diasorin S.p.A. www.diasorin.com